Agenus Inc. Common Stock (AGEN) Stock
Key stats
- Market cap
- $326.68M
- Price / Earnings ratio
- 10.8x
- EPS (TTM)
- $0.67
- Volume
- Loading
- 52-week high
- $10.31
- 52-week low
- $2.71
Source: third-party data provider, as of November 13, 2026
Compare with AGEN
Recent news

Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat
Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat
AGEN

Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer
AGEN

Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
AGEN

Agenus to Provide Third Quarter 2026 Financial Report and Development Update
Agenus to Provide Third Quarter 2026 Financial Report and Development Update
AGEN
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 52.68
- MACD 12/26/9
- -0.08
- EMA 9 of MACD
- -0.19
- MACD histogram
- 0.11
- SMA 50
- $7.42
- Price below SMA 50
- EMA 50
- $7.06
- Price above EMA 50
- SMA 200
- $5.07
- Price above SMA 200
- EMA 200
- $5.44
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat
Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat
AGEN

Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer
AGEN

Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
AGEN

Agenus to Provide Third Quarter 2026 Financial Report and Development Update
Agenus to Provide Third Quarter 2026 Financial Report and Development Update
AGEN

Agenus Pivots BOT/BAL Strategy to Phase III Colon Cancer Trial
Agenus Pivots BOT/BAL Strategy to Phase III Colon Cancer Trial
AGEN

Agenus to Participate in Chardan's 10th Annual Healthcare Investor Conference
Agenus to Participate in Chardan's 10th Annual Healthcare Investor Conference
AGEN

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
AGEN

Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
AGEN

Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
AGEN

Agenus to Participate in Upcoming September Investor Conferences
Agenus to Participate in Upcoming September Investor Conferences
AGEN
News tone: automated (AI) classification of the article's content, not a price prediction.
About Agenus Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Garo H. Armen Ph.D. | Founder, Interim CFO, Principal Financial Officer, CEO & Executive Chairman | 1953 |
| Dr. Jennifer S. Buell Ph.D. | Director and President & CEO of MiNK Therapeutics | 1975 |
| Dr. Steven J. O'Day M.D., Ph.D. | Chief Medical Officer | 1961 |
| Craig Winter | Chief Information Officer | — |
| Mr. Zack Armen | Vice President of Investor Relations & Corporate Development | — |
| Ms. Stefanie Perna-Nacar | Chief Communications & Government Relations Officer | — |
| Ms. Tracy Mazza Clemente | Chief People Officer | — |
| Dr. Todd Jude Yancey M.D. | Member of Advisory Board & Chief Strategic Advisor | — |
| Dr. Robin G. Taylor M.B.A., Ph.D. | Chief Commercial Officer | — |
| Dr. Kamel Djazouli M.D. | Head of Medical Affairs | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 52.68
- MACD 12/26/9
- -0.08
- EMA 9 of MACD
- -0.19
- MACD histogram
- 0.11
- SMA 50
- $7.42
- Price below SMA 50
- EMA 50
- $7.06
- Price above EMA 50
- SMA 200
- $5.07
- Price above SMA 200
- EMA 200
- $5.44
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $16.00
- Average
- $25.00
- High
- $40.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -13.7 | +8.1 | ||||||||||
| 2022 | -20.5 | -0.4 | -5.0 | -28.0 | -13.9 | +21.2 | +31.6 | +8.9 | -24.9 | +20.1 | +7.6 | -9.1 |
| 2023 | +8.8 | -20.5 | -21.6 | -3.8 | +3.3 | +0.6 | +0.0 | -5.5 | -18.7 | -23.8 | -6.4 | +5.8 |
| 2024 | -16.6 | +5.5 | -12.1 | +3.1 | +18.3 | -1.3 | -63.8 | -13.7 | +10.7 | -17.6 | -15.6 | -26.5 |
| 2025 | +23.0 | -18.8 | -40.6 | +80.6 | +19.9 | +10.7 | +14.0 | -22.0 | -7.5 | +1.8 | +14.9 | -27.3 |
| 2026 | -12.1 | +16.4 | +0.0 | +15.0 | -8.9 | -12.1 | +119.9 | -2.7 | +24.3 | -17.9 | +10.6 |



